Tumor Size, Estrogen-receptor Status May Contribute to Survival in Breast Cancer

Share this content:
Tumor size and estrogen-receptor status contribute greatly to survival improvement in women 70 years or older.
Tumor size and estrogen-receptor status contribute greatly to survival improvement in women 70 years or older.

Within 5 years of breast cancer diagnosis, tumor size and estrogen-receptor (ER) status contribute greatly to survival improvement in women 70 years or older, according to a study published online ahead of print in the Journal of Clinical Oncology.

However, most stage-specific improvement in survival in those younger than 70 years is unexplained by tumor size and ER status.

“Breast cancer mortality began declining in many Western countries during the late 1980s,” said Ju-Hyun Park, PhD, of Dongguk University in South Korea as well as fellow study authors from the National Cancer Institute in Maryland. “We estimated the proportion of improvements in stage- and age-specific breast cancer survival in the U.S. explained by tumor size or ER status.”

The researchers estimated hazard ratios for breast cancer-specific death from time of diagnosis through Surveillance, Epidemiology, and End Results (SEER) data from 1973 to 2010, stratifying with and without tumor size and ER status.

RELATED: Modest Association Between C-reactive Protein, Breast Cancer Risk

They found that breast cancer-specific death had declined within that time, even 5 years after the time of diagnosis. Tumor size was found to account for more of the survival improvement within the first 5 years of diagnosis than later.

In addition, survival improvement in those women who were at least 70 years was found to be explained more by tumor size and ER status, while stratifying for the same factors could not explain improvement in those younger than 70.

Reference

  1. Park JH, Anderson WF, Gail MH. Improvements in US breast cancer survival and proportion explained by tumor size and estrogen-receptor status. Journal of Clinical Oncology. 2015. [epub ahead of print]. doi: 10.1200/JCO.2014.59.9191.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters